Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
6,735
archived clinical trials in
Psoriasis

Study to Assess the Efficacy and Long-term Safety of Dupilumab (REGN668/SAR231893) in Adult Participants With Moderate-to-Severe Atopic Dermatitis
A Randomized, Double-Blind, Placebo-Controlled Study to Demonstrate the Efficacy and Long-Term Safety of Dupilumab in Adult Patients With Moderate-to-Severe Atopic Dermatitis
Status: Enrolling
Updated:  10/12/2017
Clinical Research Facility
mi
from
South Burlington, VT
Study to Assess the Efficacy and Long-term Safety of Dupilumab (REGN668/SAR231893) in Adult Participants With Moderate-to-Severe Atopic Dermatitis
A Randomized, Double-Blind, Placebo-Controlled Study to Demonstrate the Efficacy and Long-Term Safety of Dupilumab in Adult Patients With Moderate-to-Severe Atopic Dermatitis
Status: Enrolling
Updated: 10/12/2017
Clinical Research Facility
mi
from
South Burlington, VT
Click here to add this to my saved trials
Study to Assess the Efficacy and Long-term Safety of Dupilumab (REGN668/SAR231893) in Adult Participants With Moderate-to-Severe Atopic Dermatitis
A Randomized, Double-Blind, Placebo-Controlled Study to Demonstrate the Efficacy and Long-Term Safety of Dupilumab in Adult Patients With Moderate-to-Severe Atopic Dermatitis
Status: Enrolling
Updated:  10/12/2017
Clinical Research Facility
mi
from
Henrico, VA
Study to Assess the Efficacy and Long-term Safety of Dupilumab (REGN668/SAR231893) in Adult Participants With Moderate-to-Severe Atopic Dermatitis
A Randomized, Double-Blind, Placebo-Controlled Study to Demonstrate the Efficacy and Long-Term Safety of Dupilumab in Adult Patients With Moderate-to-Severe Atopic Dermatitis
Status: Enrolling
Updated: 10/12/2017
Clinical Research Facility
mi
from
Henrico, VA
Click here to add this to my saved trials
Study to Assess the Efficacy and Long-term Safety of Dupilumab (REGN668/SAR231893) in Adult Participants With Moderate-to-Severe Atopic Dermatitis
A Randomized, Double-Blind, Placebo-Controlled Study to Demonstrate the Efficacy and Long-Term Safety of Dupilumab in Adult Patients With Moderate-to-Severe Atopic Dermatitis
Status: Enrolling
Updated:  10/12/2017
Clinical Research Facility
mi
from
Norfolk, VA
Study to Assess the Efficacy and Long-term Safety of Dupilumab (REGN668/SAR231893) in Adult Participants With Moderate-to-Severe Atopic Dermatitis
A Randomized, Double-Blind, Placebo-Controlled Study to Demonstrate the Efficacy and Long-Term Safety of Dupilumab in Adult Patients With Moderate-to-Severe Atopic Dermatitis
Status: Enrolling
Updated: 10/12/2017
Clinical Research Facility
mi
from
Norfolk, VA
Click here to add this to my saved trials
Study to Assess the Efficacy and Long-term Safety of Dupilumab (REGN668/SAR231893) in Adult Participants With Moderate-to-Severe Atopic Dermatitis
A Randomized, Double-Blind, Placebo-Controlled Study to Demonstrate the Efficacy and Long-Term Safety of Dupilumab in Adult Patients With Moderate-to-Severe Atopic Dermatitis
Status: Enrolling
Updated:  10/12/2017
Clinical Research Facility
mi
from
Richmond, VA
Study to Assess the Efficacy and Long-term Safety of Dupilumab (REGN668/SAR231893) in Adult Participants With Moderate-to-Severe Atopic Dermatitis
A Randomized, Double-Blind, Placebo-Controlled Study to Demonstrate the Efficacy and Long-Term Safety of Dupilumab in Adult Patients With Moderate-to-Severe Atopic Dermatitis
Status: Enrolling
Updated: 10/12/2017
Clinical Research Facility
mi
from
Richmond, VA
Click here to add this to my saved trials
Study to Assess the Efficacy and Long-term Safety of Dupilumab (REGN668/SAR231893) in Adult Participants With Moderate-to-Severe Atopic Dermatitis
A Randomized, Double-Blind, Placebo-Controlled Study to Demonstrate the Efficacy and Long-Term Safety of Dupilumab in Adult Patients With Moderate-to-Severe Atopic Dermatitis
Status: Enrolling
Updated:  10/12/2017
Clinical Research Facility
mi
from
Spokane, WA
Study to Assess the Efficacy and Long-term Safety of Dupilumab (REGN668/SAR231893) in Adult Participants With Moderate-to-Severe Atopic Dermatitis
A Randomized, Double-Blind, Placebo-Controlled Study to Demonstrate the Efficacy and Long-Term Safety of Dupilumab in Adult Patients With Moderate-to-Severe Atopic Dermatitis
Status: Enrolling
Updated: 10/12/2017
Clinical Research Facility
mi
from
Spokane, WA
Click here to add this to my saved trials
Study to Assess the Efficacy and Long-term Safety of Dupilumab (REGN668/SAR231893) in Adult Participants With Moderate-to-Severe Atopic Dermatitis
A Randomized, Double-Blind, Placebo-Controlled Study to Demonstrate the Efficacy and Long-Term Safety of Dupilumab in Adult Patients With Moderate-to-Severe Atopic Dermatitis
Status: Enrolling
Updated:  10/12/2017
Clinical Research Facility
mi
from
Saint Louis, MO
Study to Assess the Efficacy and Long-term Safety of Dupilumab (REGN668/SAR231893) in Adult Participants With Moderate-to-Severe Atopic Dermatitis
A Randomized, Double-Blind, Placebo-Controlled Study to Demonstrate the Efficacy and Long-Term Safety of Dupilumab in Adult Patients With Moderate-to-Severe Atopic Dermatitis
Status: Enrolling
Updated: 10/12/2017
Clinical Research Facility
mi
from
Saint Louis, MO
Click here to add this to my saved trials
Comparative Effectiveness of Psoriasis Treatments on Systemic Inflammation
Comparative Effectiveness of Psoriasis Treatments on Systemic Inflammation
Status: Enrolling
Updated:  10/12/2017
University Hospitals of Cleveland Medical Center
mi
from
Cleveland, OH
Comparative Effectiveness of Psoriasis Treatments on Systemic Inflammation
Comparative Effectiveness of Psoriasis Treatments on Systemic Inflammation
Status: Enrolling
Updated: 10/12/2017
University Hospitals of Cleveland Medical Center
mi
from
Cleveland, OH
Click here to add this to my saved trials
Micro-Technique Sampling
An Exploratory Comparative Pilot Study to Identify the Most Appropriate Method for Microbial Consortia Sampling From the Skin-II
Status: Enrolling
Updated:  10/30/2017
Reliance Clinical Testing Services, Inc.
mi
from
Irving, TX
Micro-Technique Sampling
An Exploratory Comparative Pilot Study to Identify the Most Appropriate Method for Microbial Consortia Sampling From the Skin-II
Status: Enrolling
Updated: 10/30/2017
Reliance Clinical Testing Services, Inc.
mi
from
Irving, TX
Click here to add this to my saved trials
Prevalence of Sleep Disturbances in Psoriasis
Prevalence of Sleep Disturbances in Psoriasis
Status: Enrolling
Updated:  11/1/2017
Wake Forest University Health Sciences, Dermatology
mi
from
Winston-Salem, NC
Prevalence of Sleep Disturbances in Psoriasis
Prevalence of Sleep Disturbances in Psoriasis
Status: Enrolling
Updated: 11/1/2017
Wake Forest University Health Sciences, Dermatology
mi
from
Winston-Salem, NC
Click here to add this to my saved trials
Using an Internet Study to Improve Adherence for Psoriasis Patients
Using an Internet Study to Improve Adherence for Psoriasis Patients
Status: Enrolling
Updated:  11/1/2017
Wake Forest School of Medicine - Dermatology Clinic
mi
from
Winston-Salem, NC
Using an Internet Study to Improve Adherence for Psoriasis Patients
Using an Internet Study to Improve Adherence for Psoriasis Patients
Status: Enrolling
Updated: 11/1/2017
Wake Forest School of Medicine - Dermatology Clinic
mi
from
Winston-Salem, NC
Click here to add this to my saved trials
A Dose-Finding Study of GSK2894512 Cream in Subjects With Plaque Psoriasis
Study 203120: A Randomized, Blinded, Vehicle-Controlled, Dose-Finding Study of GSK2894512 Cream for the Treatment of Plaque Psoriasis
Status: Enrolling
Updated:  11/1/2017
GSK Investigational Site
mi
from
Miami, FL
A Dose-Finding Study of GSK2894512 Cream in Subjects With Plaque Psoriasis
Study 203120: A Randomized, Blinded, Vehicle-Controlled, Dose-Finding Study of GSK2894512 Cream for the Treatment of Plaque Psoriasis
Status: Enrolling
Updated: 11/1/2017
GSK Investigational Site
mi
from
Miami, FL
Click here to add this to my saved trials
A Dose-Finding Study of GSK2894512 Cream in Subjects With Plaque Psoriasis
Study 203120: A Randomized, Blinded, Vehicle-Controlled, Dose-Finding Study of GSK2894512 Cream for the Treatment of Plaque Psoriasis
Status: Enrolling
Updated:  11/1/2017
GSK Investigational Site
mi
from
Louisville, KY
A Dose-Finding Study of GSK2894512 Cream in Subjects With Plaque Psoriasis
Study 203120: A Randomized, Blinded, Vehicle-Controlled, Dose-Finding Study of GSK2894512 Cream for the Treatment of Plaque Psoriasis
Status: Enrolling
Updated: 11/1/2017
GSK Investigational Site
mi
from
Louisville, KY
Click here to add this to my saved trials
A Dose-Finding Study of GSK2894512 Cream in Subjects With Plaque Psoriasis
Study 203120: A Randomized, Blinded, Vehicle-Controlled, Dose-Finding Study of GSK2894512 Cream for the Treatment of Plaque Psoriasis
Status: Enrolling
Updated:  11/1/2017
GSK Investigational Site
mi
from
Houston, TX
A Dose-Finding Study of GSK2894512 Cream in Subjects With Plaque Psoriasis
Study 203120: A Randomized, Blinded, Vehicle-Controlled, Dose-Finding Study of GSK2894512 Cream for the Treatment of Plaque Psoriasis
Status: Enrolling
Updated: 11/1/2017
GSK Investigational Site
mi
from
Houston, TX
Click here to add this to my saved trials
A Dose-Finding Study of GSK2894512 Cream in Subjects With Plaque Psoriasis
Study 203120: A Randomized, Blinded, Vehicle-Controlled, Dose-Finding Study of GSK2894512 Cream for the Treatment of Plaque Psoriasis
Status: Enrolling
Updated:  11/1/2017
GSK Investigational Site
mi
from
San Antonio, TX
A Dose-Finding Study of GSK2894512 Cream in Subjects With Plaque Psoriasis
Study 203120: A Randomized, Blinded, Vehicle-Controlled, Dose-Finding Study of GSK2894512 Cream for the Treatment of Plaque Psoriasis
Status: Enrolling
Updated: 11/1/2017
GSK Investigational Site
mi
from
San Antonio, TX
Click here to add this to my saved trials
A Dose-Finding Study of GSK2894512 Cream in Subjects With Plaque Psoriasis
Study 203120: A Randomized, Blinded, Vehicle-Controlled, Dose-Finding Study of GSK2894512 Cream for the Treatment of Plaque Psoriasis
Status: Enrolling
Updated:  11/1/2017
GSK Investigational Site
mi
from
San Diego, CA
A Dose-Finding Study of GSK2894512 Cream in Subjects With Plaque Psoriasis
Study 203120: A Randomized, Blinded, Vehicle-Controlled, Dose-Finding Study of GSK2894512 Cream for the Treatment of Plaque Psoriasis
Status: Enrolling
Updated: 11/1/2017
GSK Investigational Site
mi
from
San Diego, CA
Click here to add this to my saved trials
A Dose-Finding Study of GSK2894512 Cream in Subjects With Plaque Psoriasis
Study 203120: A Randomized, Blinded, Vehicle-Controlled, Dose-Finding Study of GSK2894512 Cream for the Treatment of Plaque Psoriasis
Status: Enrolling
Updated:  11/1/2017
GSK Investigational Site
mi
from
North Logan, CT
A Dose-Finding Study of GSK2894512 Cream in Subjects With Plaque Psoriasis
Study 203120: A Randomized, Blinded, Vehicle-Controlled, Dose-Finding Study of GSK2894512 Cream for the Treatment of Plaque Psoriasis
Status: Enrolling
Updated: 11/1/2017
GSK Investigational Site
mi
from
North Logan, CT
Click here to add this to my saved trials
A Dose-Finding Study of GSK2894512 Cream in Subjects With Plaque Psoriasis
Study 203120: A Randomized, Blinded, Vehicle-Controlled, Dose-Finding Study of GSK2894512 Cream for the Treatment of Plaque Psoriasis
Status: Enrolling
Updated:  11/1/2017
GSK Investigational Site
mi
from
Chicago, IL
A Dose-Finding Study of GSK2894512 Cream in Subjects With Plaque Psoriasis
Study 203120: A Randomized, Blinded, Vehicle-Controlled, Dose-Finding Study of GSK2894512 Cream for the Treatment of Plaque Psoriasis
Status: Enrolling
Updated: 11/1/2017
GSK Investigational Site
mi
from
Chicago, IL
Click here to add this to my saved trials
A Dose-Finding Study of GSK2894512 Cream in Subjects With Plaque Psoriasis
Study 203120: A Randomized, Blinded, Vehicle-Controlled, Dose-Finding Study of GSK2894512 Cream for the Treatment of Plaque Psoriasis
Status: Enrolling
Updated:  11/1/2017
GSK Investigational Site
mi
from
Plainfield, IN
A Dose-Finding Study of GSK2894512 Cream in Subjects With Plaque Psoriasis
Study 203120: A Randomized, Blinded, Vehicle-Controlled, Dose-Finding Study of GSK2894512 Cream for the Treatment of Plaque Psoriasis
Status: Enrolling
Updated: 11/1/2017
GSK Investigational Site
mi
from
Plainfield, IN
Click here to add this to my saved trials
A Dose-Finding Study of GSK2894512 Cream in Subjects With Plaque Psoriasis
Study 203120: A Randomized, Blinded, Vehicle-Controlled, Dose-Finding Study of GSK2894512 Cream for the Treatment of Plaque Psoriasis
Status: Enrolling
Updated:  11/1/2017
GSK Investigational Site
mi
from
Overland Park, KA
A Dose-Finding Study of GSK2894512 Cream in Subjects With Plaque Psoriasis
Study 203120: A Randomized, Blinded, Vehicle-Controlled, Dose-Finding Study of GSK2894512 Cream for the Treatment of Plaque Psoriasis
Status: Enrolling
Updated: 11/1/2017
GSK Investigational Site
mi
from
Overland Park, KA
Click here to add this to my saved trials
A Dose-Finding Study of GSK2894512 Cream in Subjects With Plaque Psoriasis
Study 203120: A Randomized, Blinded, Vehicle-Controlled, Dose-Finding Study of GSK2894512 Cream for the Treatment of Plaque Psoriasis
Status: Enrolling
Updated:  11/1/2017
GSK Investigational Site
mi
from
High Point, NC
A Dose-Finding Study of GSK2894512 Cream in Subjects With Plaque Psoriasis
Study 203120: A Randomized, Blinded, Vehicle-Controlled, Dose-Finding Study of GSK2894512 Cream for the Treatment of Plaque Psoriasis
Status: Enrolling
Updated: 11/1/2017
GSK Investigational Site
mi
from
High Point, NC
Click here to add this to my saved trials
A Dose-Finding Study of GSK2894512 Cream in Subjects With Plaque Psoriasis
Study 203120: A Randomized, Blinded, Vehicle-Controlled, Dose-Finding Study of GSK2894512 Cream for the Treatment of Plaque Psoriasis
Status: Enrolling
Updated:  11/1/2017
GSK Investigational Site
mi
from
Philadelphia, PA
A Dose-Finding Study of GSK2894512 Cream in Subjects With Plaque Psoriasis
Study 203120: A Randomized, Blinded, Vehicle-Controlled, Dose-Finding Study of GSK2894512 Cream for the Treatment of Plaque Psoriasis
Status: Enrolling
Updated: 11/1/2017
GSK Investigational Site
mi
from
Philadelphia, PA
Click here to add this to my saved trials
A Dose-Finding Study of GSK2894512 Cream in Subjects With Plaque Psoriasis
Study 203120: A Randomized, Blinded, Vehicle-Controlled, Dose-Finding Study of GSK2894512 Cream for the Treatment of Plaque Psoriasis
Status: Enrolling
Updated:  11/1/2017
GSK Investigational Site
mi
from
Pittsburgh, PA
A Dose-Finding Study of GSK2894512 Cream in Subjects With Plaque Psoriasis
Study 203120: A Randomized, Blinded, Vehicle-Controlled, Dose-Finding Study of GSK2894512 Cream for the Treatment of Plaque Psoriasis
Status: Enrolling
Updated: 11/1/2017
GSK Investigational Site
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
A Dose-Finding Study of GSK2894512 Cream in Subjects With Plaque Psoriasis
Study 203120: A Randomized, Blinded, Vehicle-Controlled, Dose-Finding Study of GSK2894512 Cream for the Treatment of Plaque Psoriasis
Status: Enrolling
Updated:  11/1/2017
GSK Investigational Site
mi
from
Johnston, RI
A Dose-Finding Study of GSK2894512 Cream in Subjects With Plaque Psoriasis
Study 203120: A Randomized, Blinded, Vehicle-Controlled, Dose-Finding Study of GSK2894512 Cream for the Treatment of Plaque Psoriasis
Status: Enrolling
Updated: 11/1/2017
GSK Investigational Site
mi
from
Johnston, RI
Click here to add this to my saved trials
A Dose-Finding Study of GSK2894512 Cream in Subjects With Plaque Psoriasis
Study 203120: A Randomized, Blinded, Vehicle-Controlled, Dose-Finding Study of GSK2894512 Cream for the Treatment of Plaque Psoriasis
Status: Enrolling
Updated:  11/1/2017
GSK Investigational Site
mi
from
Goodlettsville, TN
A Dose-Finding Study of GSK2894512 Cream in Subjects With Plaque Psoriasis
Study 203120: A Randomized, Blinded, Vehicle-Controlled, Dose-Finding Study of GSK2894512 Cream for the Treatment of Plaque Psoriasis
Status: Enrolling
Updated: 11/1/2017
GSK Investigational Site
mi
from
Goodlettsville, TN
Click here to add this to my saved trials
A Dose-Finding Study of GSK2894512 Cream in Subjects With Plaque Psoriasis
Study 203120: A Randomized, Blinded, Vehicle-Controlled, Dose-Finding Study of GSK2894512 Cream for the Treatment of Plaque Psoriasis
Status: Enrolling
Updated:  11/1/2017
GSK Investigational Site
mi
from
Austin, TX
A Dose-Finding Study of GSK2894512 Cream in Subjects With Plaque Psoriasis
Study 203120: A Randomized, Blinded, Vehicle-Controlled, Dose-Finding Study of GSK2894512 Cream for the Treatment of Plaque Psoriasis
Status: Enrolling
Updated: 11/1/2017
GSK Investigational Site
mi
from
Austin, TX
Click here to add this to my saved trials
A Dose-Finding Study of GSK2894512 Cream in Subjects With Plaque Psoriasis
Study 203120: A Randomized, Blinded, Vehicle-Controlled, Dose-Finding Study of GSK2894512 Cream for the Treatment of Plaque Psoriasis
Status: Enrolling
Updated:  11/1/2017
GSK Investigational Site
mi
from
Webster, TX
A Dose-Finding Study of GSK2894512 Cream in Subjects With Plaque Psoriasis
Study 203120: A Randomized, Blinded, Vehicle-Controlled, Dose-Finding Study of GSK2894512 Cream for the Treatment of Plaque Psoriasis
Status: Enrolling
Updated: 11/1/2017
GSK Investigational Site
mi
from
Webster, TX
Click here to add this to my saved trials
A Dose-Finding Study of GSK2894512 Cream in Subjects With Plaque Psoriasis
Study 203120: A Randomized, Blinded, Vehicle-Controlled, Dose-Finding Study of GSK2894512 Cream for the Treatment of Plaque Psoriasis
Status: Enrolling
Updated:  11/1/2017
GSK Investigational Site
mi
from
Seattle, WA
A Dose-Finding Study of GSK2894512 Cream in Subjects With Plaque Psoriasis
Study 203120: A Randomized, Blinded, Vehicle-Controlled, Dose-Finding Study of GSK2894512 Cream for the Treatment of Plaque Psoriasis
Status: Enrolling
Updated: 11/1/2017
GSK Investigational Site
mi
from
Seattle, WA
Click here to add this to my saved trials
A Dose-Finding Study of GSK2894512 Cream in Subjects With Plaque Psoriasis
Study 203120: A Randomized, Blinded, Vehicle-Controlled, Dose-Finding Study of GSK2894512 Cream for the Treatment of Plaque Psoriasis
Status: Enrolling
Updated:  11/1/2017
GSK Investigational Site
mi
from
Surrey,
A Dose-Finding Study of GSK2894512 Cream in Subjects With Plaque Psoriasis
Study 203120: A Randomized, Blinded, Vehicle-Controlled, Dose-Finding Study of GSK2894512 Cream for the Treatment of Plaque Psoriasis
Status: Enrolling
Updated: 11/1/2017
GSK Investigational Site
mi
from
Surrey,
Click here to add this to my saved trials
A Dose-Finding Study of GSK2894512 Cream in Subjects With Plaque Psoriasis
Study 203120: A Randomized, Blinded, Vehicle-Controlled, Dose-Finding Study of GSK2894512 Cream for the Treatment of Plaque Psoriasis
Status: Enrolling
Updated:  11/1/2017
GSK Investigational Site
mi
from
Fort Gratiot Township, MI
A Dose-Finding Study of GSK2894512 Cream in Subjects With Plaque Psoriasis
Study 203120: A Randomized, Blinded, Vehicle-Controlled, Dose-Finding Study of GSK2894512 Cream for the Treatment of Plaque Psoriasis
Status: Enrolling
Updated: 11/1/2017
GSK Investigational Site
mi
from
Fort Gratiot Township, MI
Click here to add this to my saved trials
A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of ABBV-553 in Healthy Volunteers and in Subjects With Psoriasis and Efficacy of ABBV-553 in Subjects With Psoriasis
A Randomized, Double-Blind, Placebo-Controlled, Multiple-Dose Study to Evaluate the Pharmacokinetics, Safety and Tolerability of ABBV-553 in Healthy Volunteers and in Subjects With Psoriasis and Efficacy of ABBV-553 in Subjects With Psoriasis
Status: Enrolling
Updated:  11/2/2017
Abbvie Clinical Pharmacology Research Unit /ID# 163866
mi
from
Grayslake, IL
A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of ABBV-553 in Healthy Volunteers and in Subjects With Psoriasis and Efficacy of ABBV-553 in Subjects With Psoriasis
A Randomized, Double-Blind, Placebo-Controlled, Multiple-Dose Study to Evaluate the Pharmacokinetics, Safety and Tolerability of ABBV-553 in Healthy Volunteers and in Subjects With Psoriasis and Efficacy of ABBV-553 in Subjects With Psoriasis
Status: Enrolling
Updated: 11/2/2017
Abbvie Clinical Pharmacology Research Unit /ID# 163866
mi
from
Grayslake, IL
Click here to add this to my saved trials
A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of ABBV-553 in Healthy Volunteers and in Subjects With Psoriasis and Efficacy of ABBV-553 in Subjects With Psoriasis
A Randomized, Double-Blind, Placebo-Controlled, Multiple-Dose Study to Evaluate the Pharmacokinetics, Safety and Tolerability of ABBV-553 in Healthy Volunteers and in Subjects With Psoriasis and Efficacy of ABBV-553 in Subjects With Psoriasis
Status: Enrolling
Updated:  11/2/2017
Anaheim Clinical Trials LLC /ID# 164101
mi
from
Anaheim, CA
A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of ABBV-553 in Healthy Volunteers and in Subjects With Psoriasis and Efficacy of ABBV-553 in Subjects With Psoriasis
A Randomized, Double-Blind, Placebo-Controlled, Multiple-Dose Study to Evaluate the Pharmacokinetics, Safety and Tolerability of ABBV-553 in Healthy Volunteers and in Subjects With Psoriasis and Efficacy of ABBV-553 in Subjects With Psoriasis
Status: Enrolling
Updated: 11/2/2017
Anaheim Clinical Trials LLC /ID# 164101
mi
from
Anaheim, CA
Click here to add this to my saved trials
A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of ABBV-553 in Healthy Volunteers and in Subjects With Psoriasis and Efficacy of ABBV-553 in Subjects With Psoriasis
A Randomized, Double-Blind, Placebo-Controlled, Multiple-Dose Study to Evaluate the Pharmacokinetics, Safety and Tolerability of ABBV-553 in Healthy Volunteers and in Subjects With Psoriasis and Efficacy of ABBV-553 in Subjects With Psoriasis
Status: Enrolling
Updated:  11/2/2017
Progressive Medical Research /ID# 163868
mi
from
Port Orange, FL
A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of ABBV-553 in Healthy Volunteers and in Subjects With Psoriasis and Efficacy of ABBV-553 in Subjects With Psoriasis
A Randomized, Double-Blind, Placebo-Controlled, Multiple-Dose Study to Evaluate the Pharmacokinetics, Safety and Tolerability of ABBV-553 in Healthy Volunteers and in Subjects With Psoriasis and Efficacy of ABBV-553 in Subjects With Psoriasis
Status: Enrolling
Updated: 11/2/2017
Progressive Medical Research /ID# 163868
mi
from
Port Orange, FL
Click here to add this to my saved trials
A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of ABBV-553 in Healthy Volunteers and in Subjects With Psoriasis and Efficacy of ABBV-553 in Subjects With Psoriasis
A Randomized, Double-Blind, Placebo-Controlled, Multiple-Dose Study to Evaluate the Pharmacokinetics, Safety and Tolerability of ABBV-553 in Healthy Volunteers and in Subjects With Psoriasis and Efficacy of ABBV-553 in Subjects With Psoriasis
Status: Enrolling
Updated:  11/2/2017
Providence Clinical Research /ID# 163867
mi
from
Toluca, CA
A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of ABBV-553 in Healthy Volunteers and in Subjects With Psoriasis and Efficacy of ABBV-553 in Subjects With Psoriasis
A Randomized, Double-Blind, Placebo-Controlled, Multiple-Dose Study to Evaluate the Pharmacokinetics, Safety and Tolerability of ABBV-553 in Healthy Volunteers and in Subjects With Psoriasis and Efficacy of ABBV-553 in Subjects With Psoriasis
Status: Enrolling
Updated: 11/2/2017
Providence Clinical Research /ID# 163867
mi
from
Toluca, CA
Click here to add this to my saved trials
A Study of Ixekizumab (LY2439821) in Participants With Active Psoriatic Arthritis
A Multicenter, Randomized, Double-Blind, Placebo Controlled 24-Week Study Followed by Long Term Evaluation of Efficacy and Safety of Ixekizumab (LY2439821) in Biologic Disease-Modifying Antirheumatic Drug-Experienced Patients With Active Psoriatic Arthritis
Status: Enrolling
Updated:  11/17/2017
Rheumatology Associates, PC
mi
from
Birmingham, AL
A Study of Ixekizumab (LY2439821) in Participants With Active Psoriatic Arthritis
A Multicenter, Randomized, Double-Blind, Placebo Controlled 24-Week Study Followed by Long Term Evaluation of Efficacy and Safety of Ixekizumab (LY2439821) in Biologic Disease-Modifying Antirheumatic Drug-Experienced Patients With Active Psoriatic Arthritis
Status: Enrolling
Updated: 11/17/2017
Rheumatology Associates, PC
mi
from
Birmingham, AL
Click here to add this to my saved trials
A Study of Ixekizumab (LY2439821) in Participants With Active Psoriatic Arthritis
A Multicenter, Randomized, Double-Blind, Placebo Controlled 24-Week Study Followed by Long Term Evaluation of Efficacy and Safety of Ixekizumab (LY2439821) in Biologic Disease-Modifying Antirheumatic Drug-Experienced Patients With Active Psoriatic Arthritis
Status: Enrolling
Updated:  11/17/2017
Arizona Arthritis and Rheumatology Research
mi
from
Glendale, AZ
A Study of Ixekizumab (LY2439821) in Participants With Active Psoriatic Arthritis
A Multicenter, Randomized, Double-Blind, Placebo Controlled 24-Week Study Followed by Long Term Evaluation of Efficacy and Safety of Ixekizumab (LY2439821) in Biologic Disease-Modifying Antirheumatic Drug-Experienced Patients With Active Psoriatic Arthritis
Status: Enrolling
Updated: 11/17/2017
Arizona Arthritis and Rheumatology Research
mi
from
Glendale, AZ
Click here to add this to my saved trials
A Study of Ixekizumab (LY2439821) in Participants With Active Psoriatic Arthritis
A Multicenter, Randomized, Double-Blind, Placebo Controlled 24-Week Study Followed by Long Term Evaluation of Efficacy and Safety of Ixekizumab (LY2439821) in Biologic Disease-Modifying Antirheumatic Drug-Experienced Patients With Active Psoriatic Arthritis
Status: Enrolling
Updated:  11/17/2017
Arizona Arthritis & Rheumatology Associates, P. C.
mi
from
Mesa, AZ
A Study of Ixekizumab (LY2439821) in Participants With Active Psoriatic Arthritis
A Multicenter, Randomized, Double-Blind, Placebo Controlled 24-Week Study Followed by Long Term Evaluation of Efficacy and Safety of Ixekizumab (LY2439821) in Biologic Disease-Modifying Antirheumatic Drug-Experienced Patients With Active Psoriatic Arthritis
Status: Enrolling
Updated: 11/17/2017
Arizona Arthritis & Rheumatology Associates, P. C.
mi
from
Mesa, AZ
Click here to add this to my saved trials
A Study of Ixekizumab (LY2439821) in Participants With Active Psoriatic Arthritis
A Multicenter, Randomized, Double-Blind, Placebo Controlled 24-Week Study Followed by Long Term Evaluation of Efficacy and Safety of Ixekizumab (LY2439821) in Biologic Disease-Modifying Antirheumatic Drug-Experienced Patients With Active Psoriatic Arthritis
Status: Enrolling
Updated:  11/17/2017
Arizona Arthritis Research PLC
mi
from
Phoenix, AZ
A Study of Ixekizumab (LY2439821) in Participants With Active Psoriatic Arthritis
A Multicenter, Randomized, Double-Blind, Placebo Controlled 24-Week Study Followed by Long Term Evaluation of Efficacy and Safety of Ixekizumab (LY2439821) in Biologic Disease-Modifying Antirheumatic Drug-Experienced Patients With Active Psoriatic Arthritis
Status: Enrolling
Updated: 11/17/2017
Arizona Arthritis Research PLC
mi
from
Phoenix, AZ
Click here to add this to my saved trials
A Study of Ixekizumab (LY2439821) in Participants With Active Psoriatic Arthritis
A Multicenter, Randomized, Double-Blind, Placebo Controlled 24-Week Study Followed by Long Term Evaluation of Efficacy and Safety of Ixekizumab (LY2439821) in Biologic Disease-Modifying Antirheumatic Drug-Experienced Patients With Active Psoriatic Arthritis
Status: Enrolling
Updated:  11/17/2017
Little Rock Diagnostic Clinic
mi
from
Little Rock, AR
A Study of Ixekizumab (LY2439821) in Participants With Active Psoriatic Arthritis
A Multicenter, Randomized, Double-Blind, Placebo Controlled 24-Week Study Followed by Long Term Evaluation of Efficacy and Safety of Ixekizumab (LY2439821) in Biologic Disease-Modifying Antirheumatic Drug-Experienced Patients With Active Psoriatic Arthritis
Status: Enrolling
Updated: 11/17/2017
Little Rock Diagnostic Clinic
mi
from
Little Rock, AR
Click here to add this to my saved trials
A Study of Ixekizumab (LY2439821) in Participants With Active Psoriatic Arthritis
A Multicenter, Randomized, Double-Blind, Placebo Controlled 24-Week Study Followed by Long Term Evaluation of Efficacy and Safety of Ixekizumab (LY2439821) in Biologic Disease-Modifying Antirheumatic Drug-Experienced Patients With Active Psoriatic Arthritis
Status: Enrolling
Updated:  11/17/2017
The University of California, San Diego
mi
from
La Jolla, CA
A Study of Ixekizumab (LY2439821) in Participants With Active Psoriatic Arthritis
A Multicenter, Randomized, Double-Blind, Placebo Controlled 24-Week Study Followed by Long Term Evaluation of Efficacy and Safety of Ixekizumab (LY2439821) in Biologic Disease-Modifying Antirheumatic Drug-Experienced Patients With Active Psoriatic Arthritis
Status: Enrolling
Updated: 11/17/2017
The University of California, San Diego
mi
from
La Jolla, CA
Click here to add this to my saved trials
A Study of Ixekizumab (LY2439821) in Participants With Active Psoriatic Arthritis
A Multicenter, Randomized, Double-Blind, Placebo Controlled 24-Week Study Followed by Long Term Evaluation of Efficacy and Safety of Ixekizumab (LY2439821) in Biologic Disease-Modifying Antirheumatic Drug-Experienced Patients With Active Psoriatic Arthritis
Status: Enrolling
Updated:  11/17/2017
Purushotham & Akther Kotha MD Inc
mi
from
LA Mesa, CA
A Study of Ixekizumab (LY2439821) in Participants With Active Psoriatic Arthritis
A Multicenter, Randomized, Double-Blind, Placebo Controlled 24-Week Study Followed by Long Term Evaluation of Efficacy and Safety of Ixekizumab (LY2439821) in Biologic Disease-Modifying Antirheumatic Drug-Experienced Patients With Active Psoriatic Arthritis
Status: Enrolling
Updated: 11/17/2017
Purushotham & Akther Kotha MD Inc
mi
from
LA Mesa, CA
Click here to add this to my saved trials
A Study of Ixekizumab (LY2439821) in Participants With Active Psoriatic Arthritis
A Multicenter, Randomized, Double-Blind, Placebo Controlled 24-Week Study Followed by Long Term Evaluation of Efficacy and Safety of Ixekizumab (LY2439821) in Biologic Disease-Modifying Antirheumatic Drug-Experienced Patients With Active Psoriatic Arthritis
Status: Enrolling
Updated:  11/17/2017
Stanford University Hospital
mi
from
Palo Alto, CA
A Study of Ixekizumab (LY2439821) in Participants With Active Psoriatic Arthritis
A Multicenter, Randomized, Double-Blind, Placebo Controlled 24-Week Study Followed by Long Term Evaluation of Efficacy and Safety of Ixekizumab (LY2439821) in Biologic Disease-Modifying Antirheumatic Drug-Experienced Patients With Active Psoriatic Arthritis
Status: Enrolling
Updated: 11/17/2017
Stanford University Hospital
mi
from
Palo Alto, CA
Click here to add this to my saved trials
A Study of Ixekizumab (LY2439821) in Participants With Active Psoriatic Arthritis
A Multicenter, Randomized, Double-Blind, Placebo Controlled 24-Week Study Followed by Long Term Evaluation of Efficacy and Safety of Ixekizumab (LY2439821) in Biologic Disease-Modifying Antirheumatic Drug-Experienced Patients With Active Psoriatic Arthritis
Status: Enrolling
Updated:  11/17/2017
East Bay Rheumatology Medical Group, Inc.
mi
from
San Leandro, CA
A Study of Ixekizumab (LY2439821) in Participants With Active Psoriatic Arthritis
A Multicenter, Randomized, Double-Blind, Placebo Controlled 24-Week Study Followed by Long Term Evaluation of Efficacy and Safety of Ixekizumab (LY2439821) in Biologic Disease-Modifying Antirheumatic Drug-Experienced Patients With Active Psoriatic Arthritis
Status: Enrolling
Updated: 11/17/2017
East Bay Rheumatology Medical Group, Inc.
mi
from
San Leandro, CA
Click here to add this to my saved trials
A Study of Ixekizumab (LY2439821) in Participants With Active Psoriatic Arthritis
A Multicenter, Randomized, Double-Blind, Placebo Controlled 24-Week Study Followed by Long Term Evaluation of Efficacy and Safety of Ixekizumab (LY2439821) in Biologic Disease-Modifying Antirheumatic Drug-Experienced Patients With Active Psoriatic Arthritis
Status: Enrolling
Updated:  11/17/2017
Office: Dr Robin K Dore
mi
from
Tustin, CA
A Study of Ixekizumab (LY2439821) in Participants With Active Psoriatic Arthritis
A Multicenter, Randomized, Double-Blind, Placebo Controlled 24-Week Study Followed by Long Term Evaluation of Efficacy and Safety of Ixekizumab (LY2439821) in Biologic Disease-Modifying Antirheumatic Drug-Experienced Patients With Active Psoriatic Arthritis
Status: Enrolling
Updated: 11/17/2017
Office: Dr Robin K Dore
mi
from
Tustin, CA
Click here to add this to my saved trials
A Study of Ixekizumab (LY2439821) in Participants With Active Psoriatic Arthritis
A Multicenter, Randomized, Double-Blind, Placebo Controlled 24-Week Study Followed by Long Term Evaluation of Efficacy and Safety of Ixekizumab (LY2439821) in Biologic Disease-Modifying Antirheumatic Drug-Experienced Patients With Active Psoriatic Arthritis
Status: Enrolling
Updated:  11/17/2017
Rheumatology Associates of South Florida
mi
from
Boca Raton, FL
A Study of Ixekizumab (LY2439821) in Participants With Active Psoriatic Arthritis
A Multicenter, Randomized, Double-Blind, Placebo Controlled 24-Week Study Followed by Long Term Evaluation of Efficacy and Safety of Ixekizumab (LY2439821) in Biologic Disease-Modifying Antirheumatic Drug-Experienced Patients With Active Psoriatic Arthritis
Status: Enrolling
Updated: 11/17/2017
Rheumatology Associates of South Florida
mi
from
Boca Raton, FL
Click here to add this to my saved trials
A Study of Ixekizumab (LY2439821) in Participants With Active Psoriatic Arthritis
A Multicenter, Randomized, Double-Blind, Placebo Controlled 24-Week Study Followed by Long Term Evaluation of Efficacy and Safety of Ixekizumab (LY2439821) in Biologic Disease-Modifying Antirheumatic Drug-Experienced Patients With Active Psoriatic Arthritis
Status: Enrolling
Updated:  11/17/2017
Jeffrey Alper, MD Research
mi
from
Naples, FL
A Study of Ixekizumab (LY2439821) in Participants With Active Psoriatic Arthritis
A Multicenter, Randomized, Double-Blind, Placebo Controlled 24-Week Study Followed by Long Term Evaluation of Efficacy and Safety of Ixekizumab (LY2439821) in Biologic Disease-Modifying Antirheumatic Drug-Experienced Patients With Active Psoriatic Arthritis
Status: Enrolling
Updated: 11/17/2017
Jeffrey Alper, MD Research
mi
from
Naples, FL
Click here to add this to my saved trials
A Study of Ixekizumab (LY2439821) in Participants With Active Psoriatic Arthritis
A Multicenter, Randomized, Double-Blind, Placebo Controlled 24-Week Study Followed by Long Term Evaluation of Efficacy and Safety of Ixekizumab (LY2439821) in Biologic Disease-Modifying Antirheumatic Drug-Experienced Patients With Active Psoriatic Arthritis
Status: Enrolling
Updated:  11/17/2017
Arthritis & osteoporosis treatment center,PA
mi
from
Orange Park, FL
A Study of Ixekizumab (LY2439821) in Participants With Active Psoriatic Arthritis
A Multicenter, Randomized, Double-Blind, Placebo Controlled 24-Week Study Followed by Long Term Evaluation of Efficacy and Safety of Ixekizumab (LY2439821) in Biologic Disease-Modifying Antirheumatic Drug-Experienced Patients With Active Psoriatic Arthritis
Status: Enrolling
Updated: 11/17/2017
Arthritis & osteoporosis treatment center,PA
mi
from
Orange Park, FL
Click here to add this to my saved trials
A Study of Ixekizumab (LY2439821) in Participants With Active Psoriatic Arthritis
A Multicenter, Randomized, Double-Blind, Placebo Controlled 24-Week Study Followed by Long Term Evaluation of Efficacy and Safety of Ixekizumab (LY2439821) in Biologic Disease-Modifying Antirheumatic Drug-Experienced Patients With Active Psoriatic Arthritis
Status: Enrolling
Updated:  11/17/2017
Gulf Clinical Research Institute
mi
from
Pensacola, FL
A Study of Ixekizumab (LY2439821) in Participants With Active Psoriatic Arthritis
A Multicenter, Randomized, Double-Blind, Placebo Controlled 24-Week Study Followed by Long Term Evaluation of Efficacy and Safety of Ixekizumab (LY2439821) in Biologic Disease-Modifying Antirheumatic Drug-Experienced Patients With Active Psoriatic Arthritis
Status: Enrolling
Updated: 11/17/2017
Gulf Clinical Research Institute
mi
from
Pensacola, FL
Click here to add this to my saved trials
A Study of Ixekizumab (LY2439821) in Participants With Active Psoriatic Arthritis
A Multicenter, Randomized, Double-Blind, Placebo Controlled 24-Week Study Followed by Long Term Evaluation of Efficacy and Safety of Ixekizumab (LY2439821) in Biologic Disease-Modifying Antirheumatic Drug-Experienced Patients With Active Psoriatic Arthritis
Status: Enrolling
Updated:  11/17/2017
Diagnostic Rheumatology and Research PC
mi
from
Indianapolis, IN
A Study of Ixekizumab (LY2439821) in Participants With Active Psoriatic Arthritis
A Multicenter, Randomized, Double-Blind, Placebo Controlled 24-Week Study Followed by Long Term Evaluation of Efficacy and Safety of Ixekizumab (LY2439821) in Biologic Disease-Modifying Antirheumatic Drug-Experienced Patients With Active Psoriatic Arthritis
Status: Enrolling
Updated: 11/17/2017
Diagnostic Rheumatology and Research PC
mi
from
Indianapolis, IN
Click here to add this to my saved trials
A Study of Ixekizumab (LY2439821) in Participants With Active Psoriatic Arthritis
A Multicenter, Randomized, Double-Blind, Placebo Controlled 24-Week Study Followed by Long Term Evaluation of Efficacy and Safety of Ixekizumab (LY2439821) in Biologic Disease-Modifying Antirheumatic Drug-Experienced Patients With Active Psoriatic Arthritis
Status: Enrolling
Updated:  11/17/2017
Physician's Clinic of Iowa, P.C.
mi
from
Cedar Rapids, IA
A Study of Ixekizumab (LY2439821) in Participants With Active Psoriatic Arthritis
A Multicenter, Randomized, Double-Blind, Placebo Controlled 24-Week Study Followed by Long Term Evaluation of Efficacy and Safety of Ixekizumab (LY2439821) in Biologic Disease-Modifying Antirheumatic Drug-Experienced Patients With Active Psoriatic Arthritis
Status: Enrolling
Updated: 11/17/2017
Physician's Clinic of Iowa, P.C.
mi
from
Cedar Rapids, IA
Click here to add this to my saved trials
A Study of Ixekizumab (LY2439821) in Participants With Active Psoriatic Arthritis
A Multicenter, Randomized, Double-Blind, Placebo Controlled 24-Week Study Followed by Long Term Evaluation of Efficacy and Safety of Ixekizumab (LY2439821) in Biologic Disease-Modifying Antirheumatic Drug-Experienced Patients With Active Psoriatic Arthritis
Status: Enrolling
Updated:  11/17/2017
Heartland Research Associates, LLC
mi
from
Wichita, KA
A Study of Ixekizumab (LY2439821) in Participants With Active Psoriatic Arthritis
A Multicenter, Randomized, Double-Blind, Placebo Controlled 24-Week Study Followed by Long Term Evaluation of Efficacy and Safety of Ixekizumab (LY2439821) in Biologic Disease-Modifying Antirheumatic Drug-Experienced Patients With Active Psoriatic Arthritis
Status: Enrolling
Updated: 11/17/2017
Heartland Research Associates, LLC
mi
from
Wichita, KA
Click here to add this to my saved trials